Strategic growth Cenexi is expanding its manufacturing footprint with four production sites and a dedicated development center, indicating ongoing capacity needs and potential for outsourced CDMO partnerships, especially in sterile and cytotoxic manufacturing.

Leadership shift Recent C-suite changes, including appointment of a new CEO, suggest a strategic pivot and potential openness to new partnerships, technology investments, and process improvements that could benefit suppliers with advanced sterile and autoinjector capabilities.

Sterile focus Sterile manufacturing represents a majority of Cenexi’s core business (about 70%), signaling a strong opportunity for suppliers of sterile fill-finish technologies, cleanroom services, and related quality-compliance solutions.

Strategic partnerships Past collaborations with Crossject and international acquisition activity indicate Cenexi’s willingness to partner for device integrations, autoinjector technology, and niche dosage forms, suggesting collaboration prospects for device-compatibility packaging and development programs.

Tech-enabled Adoption of ERP and enterprise tools (SAP, Power BI, VMware) points to a tech-savvy operation open to digitalization partnerships, data analytics services, manufacturing IT security, and integrated supply chain optimization opportunities.